Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency
- PMID: 26492461
- PMCID: PMC4770368
- DOI: 10.1097/QAI.0000000000000873
Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency
Abstract
Supplemental Digital Content is Available in the Text.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures

Similar articles
-
Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.Clin Microbiol Infect. 2015 Jan;21(1):103.e1-6. doi: 10.1016/j.cmi.2014.08.002. Epub 2014 Oct 29. Clin Microbiol Infect. 2015. PMID: 25636934 Clinical Trial.
-
In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.Antimicrob Agents Chemother. 2012 Jan;56(1):137-9. doi: 10.1128/AAC.05313-11. Epub 2011 Nov 7. Antimicrob Agents Chemother. 2012. PMID: 22064539 Free PMC article.
-
Are the proposed env mutations actually associated with resistance to maraviroc?J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):550-2. doi: 10.1097/QAI.0b013e3181ba46a6. J Acquir Immune Defic Syndr. 2010. PMID: 20220379 No abstract available.
-
Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.Curr Top Med Chem. 2014;14(13):1504-14. doi: 10.2174/1568026614666140827143745. Curr Top Med Chem. 2014. PMID: 25159165 Free PMC article. Review.
-
[Pharmacological profile and clinical findings of Maraviroc (Celsentri® Tablets)].Nihon Yakurigaku Zasshi. 2010 Dec;136(6):349-58. doi: 10.1254/fpj.136.349. Nihon Yakurigaku Zasshi. 2010. PMID: 21139287 Review. Japanese. No abstract available.
Cited by
-
Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.Retrovirology. 2016 Nov 3;13(1):74. doi: 10.1186/s12977-016-0309-2. Retrovirology. 2016. PMID: 27809912 Free PMC article.
-
Cohort profile: InfCareHIV, a prospective registry-based cohort study of people with diagnosed HIV in Sweden.BMJ Open. 2023 Mar 17;13(3):e069688. doi: 10.1136/bmjopen-2022-069688. BMJ Open. 2023. PMID: 36931676 Free PMC article.
References
-
- Fenyo EM, Esbjornsson J, Medstrand P, et al. Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance. J Intern Med. 2011;270:520–531. - PubMed
-
- Jansson M, Backstrom E, Bjorndal A, et al. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. J Hum Virol. 1999;2:325–338. - PubMed
-
- Koning FA, Kwa D, Boeser-Nunnink B, et al. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis. 2003;188:864–872. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical